Celyad Oncology SA (ENXTBR: CYAD)
Health Care · Biotechnology · BE
€0.26
-7.55% today · -30.5% 1Y
Celyad Oncology SA (ENXTBR: CYAD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $14.53M and employs 17 people.
Over the last twelve months the share price has lost 30.5%, trading between 0.16 and 0.65.
Tweenvest scores Celyad Oncology SA across four factors: quality 28/100, value 58/100. Its strongest factor is value.
CYAD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.53M
- Revenue (TTM)
- $24.66K
- P/E
- 15.44
- EPS
- 0.02
- Dividend yield
- —
- Beta (5Y)
- 1.21
- 52-week high
- €0.65
- 52-week low
- €0.16
- Avg volume (3M)
- —
- Shares outstanding
- 44.76M
- Employees
- 17
- Next earnings
- —
About Celyad Oncology SA
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
- ISIN
- BE0974260896
- Founded
- 2004
- Listed since
- Jul 4, 2013
- Exchange
- Euronext Brussels
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.